iopamidol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1464	60166-93-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iopamidol iopamiron	A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures. Molecular weight: 777.09 Formula: C17H22I3N3O8 CLOGP: -1.91 LIPINSKI: 3 HAC: 11 HDO: 8 TPSA: 188.45 ALOGS: -2.99 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iopamidol
iopamiron

A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.

Molecular weight: 777.09
Formula: C17H22I3N3O8
CLOGP: -1.91
LIPINSKI: 3
HAC: 11
HDO: 8
TPSA: 188.45
ALOGS: -2.99
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	96 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	2.10 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	1530.44 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ
CL (Clearance)	1.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.28 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1985	FDA	BRACCO

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	277.17	31.94	47	2660	1078	63485237
Anaphylactic reaction	152.08	31.94	68	2639	66032	63420283
Anaphylactic shock	138.87	31.94	48	2659	23585	63462730
Contrast encephalopathy	126.17	31.94	17	2690	71	63486244
No adverse event	86.86	31.94	40	2667	41365	63444950
Urticaria	78.07	31.94	61	2646	165741	63320574
Extravasation	70.27	31.94	17	2690	2355	63483960
Anaphylactoid reaction	62.66	31.94	17	2690	3706	63482609
Throat tightness	61.57	31.94	27	2680	24860	63461455
Maternal exposure during pregnancy	61.19	31.94	60	2647	220002	63266313

Showing 1 to 10 of 20 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	273.52	25.99	49	2487	897	34953498
Anaphylactic shock	235.96	25.99	74	2462	15867	34938528
Anaphylactic reaction	140.85	25.99	61	2475	32240	34922155
Contrast media allergy	107.39	25.99	20	2516	455	34953940
Contrast encephalopathy	103.48	25.99	15	2521	62	34954333
Urticaria	84.90	25.99	54	2482	62323	34892072
Hepatic artery stenosis	71.79	25.99	12	2524	142	34954253
Pruritus	47.83	25.99	55	2481	141926	34812469
Cardio-respiratory arrest	40.73	25.99	33	2503	55240	34899155
Extravasation	37.39	25.99	11	2525	1879	34952516

Showing 1 to 10 of 15 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	505.14	24.97	91	4970	1979	79737348
Anaphylactic shock	319.62	24.97	110	4951	35886	79703441
Anaphylactic reaction	254.40	24.97	118	4943	83625	79655702
Contrast encephalopathy	220.73	24.97	32	5029	156	79739171
Urticaria	141.98	24.97	107	4954	185094	79554233
Contrast media allergy	116.84	24.97	28	5033	2494	79736833
Hepatic artery stenosis	84.11	24.97	14	5047	186	79739141
Pruritus	69.73	24.97	104	4957	394544	79344783
Drug reaction with eosinophilia and systemic symptoms	69.72	24.97	46	5015	64198	79675129
Cardio-respiratory arrest	66.39	24.97	55	5006	108455	79630872

Showing 1 to 10 of 34 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	V08AB04	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:37338	contrast media
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000180185	Radiographic Contrast Agent
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.76	acidic
pKa2	11.36	acidic
pKa3	12.12	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
000672	NDDF
109219007	SNOMEDCT_US
395754005	SNOMEDCT_US
4017756	VUID
4017756	VANDF
4399	INN_ID
4905	MMSL
5966	RXNORM
65492	PUBCHEM_CID
C0022026	UMLSCUI

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-124	INJECTION, SOLUTION	408 mg	INTRATHECAL	ANDA	21 sections
ISOVUE-M	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1411	INJECTION, SOLUTION	408 mg	INTRATHECAL	NDA	22 sections
ISOVUE-M	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1411	INJECTION, SOLUTION	408 mg	INTRATHECAL	NDA	22 sections
ISOVUE-M	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1412	INJECTION, SOLUTION	612 mg	INTRATHECAL	NDA	22 sections
ISOVUE-M	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1412	INJECTION, SOLUTION	612 mg	INTRATHECAL	NDA	22 sections
ISOVUE-M 200	HUMAN PRESCRIPTION DRUG LABEL	1	52584-411	INJECTION, SOLUTION	408 mg	INTRATHECAL	NDA	11 sections
ISOVUE200	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1314	INJECTION, SOLUTION	408 mg	INTRAVASCULAR	NDA	23 sections
ISOVUE200	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1314	INJECTION, SOLUTION	408 mg	INTRAVASCULAR	NDA	23 sections
ISOVUE200	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1314	INJECTION, SOLUTION	408 mg	INTRAVASCULAR	NDA	23 sections
ISOVUE250	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1317	INJECTION, SOLUTION	510 mg	INTRAVASCULAR	NDA	24 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next